<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109339">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02008864</url>
  </required_header>
  <id_info>
    <org_study_id>Senna in Uremic Pruritus</org_study_id>
    <nct_id>NCT02008864</nct_id>
  </id_info>
  <brief_title>Evaluating the Effect of Senna in Uremic Pruritus</brief_title>
  <official_title>Phase II Study of the Effect of Senna Alexandrina Mill. on Uremic Pruritus and Serum IL-2, INF-δ and TNF-α Levels of Hemodialysed Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uremic pruritus remains one of the most frustrating and potentially disabling symptoms in
      patients with end stage renal disease. It affect up to 90 percent of patients with end stage
      renal disease. Several hypotheses have been postulated for the possible underlying etiology,
      but none is conclusive. Aside from kidney transplantation, which is only definitive
      treatment, therapeutic approaches have largely been empirical, and no firm evident‐base
      treatments are available. The main goal of therapy remains to minimize severity of pruritus.
      In Iranian traditional medicine Cassia senna L. is used for healing uremic pruritus . In
      this study investigators considered to evaluate effect of Cassia senna L. in uremic pruritus
      by a double blind placebo control clinical trial. It is hypothesized that oral Cassia senna
      L. may attenuate uremic pruritus by decreasing serum IL‐2, IFN-γ and TNF‐α.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Severity of Pruritis, as measured by a visual analogue scale</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>A '0' score represented absence of pruritus and a '10' represented the greatest severity of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum IL‐2 level</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum INF-δ level</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum TNF-α level</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Wheat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Senna</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Senna</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Senna</intervention_name>
    <description>14 mg Senna tablet/ 2 times per day</description>
    <arm_group_label>Senna</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet/ 2 times per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemodialysis patients

          -  Suffering from pruritus for at least 6 weeks

          -  Have not responded to other drugs

        Exclusion Criteria:

          -  Dermatological disease

          -  Liver disease

          -  Metabolic disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamshid Roozbeh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdolali Mohagheghzadeh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Mehdi Sagheb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arian Kamali-Sarvestani, Pharm D</last_name>
    <role>Study Director</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 6, 2013</lastchanged_date>
  <firstreceived_date>December 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Pouya Faridi</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>End stage renal diseases</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Uremic pruritus</keyword>
  <keyword>Iranian traditional medicine</keyword>
  <keyword>Cassia angustifolia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Senna Extract</mesh_term>
    <mesh_term>Sennoside A&amp;B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
